Mucositis Clinical Trial
Official title:
Efficacy of 0.12% Chlorhexidine Gluconate for Non-surgical Treatment of Peri-implant Mucositis
The purpose of this study is to analyze the efficacy of 0.12% chlorhexidine gluconate as a chemical adjuvant for the treatment of peri-implant mucositis, in a non-surgical treatment protocol with a six-month follow-up.
Determination of the sample size was based on the sample calculation for clinical trials,
estimating a 50% success rate for the control group and 100% for the test group, which was
then averaged for the two groups. With a standardized difference and power test of 85%, a
total of 28 subjects per group were obtained.
Periapical radiographic examinations were performed before the collection of data to confirm
the absence of bone loss, and threads exposition of the implants. The following clinical
parameters were evaluated in both test and control groups; visible plaque index (VPI) and
gingival bleeding index (GBI) were obtained for full mouth (IPV and ISG) and for each
implant (VPI implant; GBI implant). For statistical purposes, percentages of faces with
biofilm and marginal bleeding at teeth and implants were calculated. These parameters were
evaluated at baseline and at one, three and six months post-therapy.
Keratinized mucosa width (KM), probing depth (PD implant), and bleeding on probing (BOP
implant) were collected for all implants with a North Carolina periodontal probe at six
sites. After data collection, an arithmetic averages of the sites with bleeding on probing,
probing depths, and keratinized mucosa were calculated at baseline, three and six months.
The peri-implant biotype for each implant was rated as thin or thick, according to probe
transparency during probing depth.
Clinical parameters were collected by two operators, calibrated by the Kappa test for the
keratinized mucosa, peri-implant biotype and probing depth.
After inclusion of the patients, anamnesis and initial examination were performed. The
subjects were randomly divided, using a simple draw, in the following two groups: Test -
(0.12% chlorhexidine digluconate associated with periodontal basic therapy) and Control -
(placebo associated with periodontal basic therapy). Data were analyzed using descriptive
and inferential statistics, with nonparametric tests, through a Statistical Package Social
Sciences software (SPSS), version 17.0 (free version). The Friedman test was used for
intragroup analysis and if any significant differences were observed, the Wilcoxon post-test
was performed. Additionally, Mann-Whitney test was used for intergroup analysis. Chi-Square
test was used to evaluate probing depth and bleeding on probing, according to the
independent variables of interest: age, sex, treatment group, keratinized mucosa,
peri-implant biotype, median VPI implant and GBI implant. Spearman correlation was also used
to correlate probing depth and bleeding on probing after six months of follow-up. The
implant was considered the unit of analysis and a value of p<0.05 was used to represent a
statistically significant difference.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02252926 -
Local Anesthetic Treatment of Oral Pain in Patients With Mucositis
|
Phase 2 | |
Completed |
NCT01155609 -
L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer
|
N/A | |
Completed |
NCT00357942 -
Topical Morphine for Stomatitis-related Pain Induced by Chemotherapy
|
Phase 4 | |
Completed |
NCT00360685 -
Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX
|
N/A | |
Completed |
NCT04586491 -
The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients
|
N/A | |
Withdrawn |
NCT02589860 -
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
|
||
Not yet recruiting |
NCT02506231 -
The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome
|
Phase 2/Phase 3 | |
Completed |
NCT02639377 -
Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis and Gingivitis
|
Phase 2 | |
Completed |
NCT00956254 -
Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis
|
Phase 3 | |
Terminated |
NCT02575313 -
The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00584597 -
A Trial of Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis
|
Phase 1 | |
Enrolling by invitation |
NCT05590117 -
Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer
|
Early Phase 1 | |
Completed |
NCT05635929 -
Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.
|
N/A | |
Completed |
NCT05181943 -
Effectiveness of Photo-biomodulation in the Treatment of Chemotherapy Induced Mucositis
|
N/A | |
Completed |
NCT03713567 -
Clinical, Immunological and Microbiological Evaluation of Experimental Gingivitis and Peri-implant Mucositis
|
N/A | |
Completed |
NCT02671812 -
Outcome After Dental Implant Treatment
|
||
Terminated |
NCT02273752 -
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
|
Phase 2 | |
Recruiting |
NCT01707641 -
Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer
|
Phase 4 | |
Completed |
NCT01015183 -
Prevention Chemotherapy Induced Mucositis by Zinc Sulfate
|
Phase 2/Phase 3 | |
Completed |
NCT00533078 -
Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies
|
Phase 2 |